Sutent for non-GIST sarcoma – pro
Suten(sunitinib)t is indicated for the treatment of gastrointestinal stromal tumor (GIST), a type of sarcoma, after disease progression on or intolerance to imatinib mesylate. Sutent is also indicated for the treatment of advanced renal cell carcinoma (RCC).
A Phase II clinical trial for sunitinib (S. George et al) in treating 53 patients with metastatic, locally advanced, or locally recurrent non-GIST sarcomas was presented in ASCO 2009. Sunitinib demonstrated notable evidence of metabolic response in several patients with non-GIST sarcoma. The relevance ofdisease control observed in subtypes with an indolent naturalhistory is unknown, however, the durable disease control observedin DSRCT, solitary fibrous tumor, and giant cell tumor of bonesuggests that future evaluation of sunitinib in these subtypes may be warranted. There are case reports for use in clear cell sarcoma patients.
A Phase II clinical trial for sunitinib (S. George et al) in treating 53 patients with metastatic, locally advanced, or locally recurrent non-GIST sarcomas was presented in ASCO 2009. Sunitinib demonstrated notable evidence of metabolic responsein several patients with non-GIST sarcoma. The relevance ofdisease control observed in subtypes with an indolent naturalhistory is unknown, however, the durable disease control observedin DSRCT, solitary fibrous tumor, and giant cell tumor of bonesuggests that future evaluation of sunitinib in these subtypesmay be warranted. There are case reports for use in clear cell sarcoma patients.
Blanca Homet Moreno, Elena Garralda Cabanas and Ricardo Hitt Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas Clinical and Translational Oncology Volume 12, Number 7, 468-472
S. Stacchiotti et al, Tumor response to sunitinib malate observed in clear-cell sarcoma Ann Oncol (2010) 21 (5): 1130-1131
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. Dec 2005;315(3):971-979.